30
Participants
Start Date
May 31, 2011
Primary Completion Date
August 31, 2012
Study Completion Date
February 28, 2015
ALT-836 in combination with gemcitabine
Study participants will receive up to four courses of a 28-day biochemotherapy with the study drug (ALT-836) and gemcitabine. Each treatment course consists of five doses of ALT-836 (on Day 1, 4, 8, 15 and 22) and three doses of gemcitabine (Day 1, 8 and 15). Participants with persistent responses will receive additional two cycles, three doses each, of standard of care gemcitabine therapy.
University of Rochester Medical Center, James P. Wilmot Cancer Center, Rochester
Carolinas Hematology-Oncology Associates, Charlotte
Emory University, Winship Cancer Institute, Atlanta
University of Iowa Hospitals and Clinics, Iowa City
Lead Sponsor
Altor BioScience
INDUSTRY